Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Kyverna Therapeutics is rated “Moderate Buy” by seven analysts, with five buys, one strong buy and one sell; the average 12-month price target is $29.00.
• KYTX opened at $6.22, near its 52-week low of $5.30 and below its 50-day and 200-day moving averages. The company reported a quarterly loss of $0.63 per share, beating expectations of a $0.68 loss.
• Institutional investors and hedge funds own 18.08% of the stock, while Kyverna continues developing KYV-101, an investigational CD19-directed CAR-T therapy for autoimmune diseases.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $29.00.

A number of research analysts have weighed in on KYTX shares. Needham & Company LLC set a $25.00 price target on shares of Kyverna Therapeutics in a research report on Friday, September 25th. HC Wainwright reissued a "buy" rating on shares of Kyverna Therapeutics in a report on Friday, September 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research note on Monday, September 21st. Benchmark restated a "buy" rating on shares of Kyverna Therapeutics in a research report on Friday, September 25th. Finally, William Blair upgraded Kyverna Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd.

Kyverna Therapeutics Price Performance

Kyverna Therapeutics stock opened at $6.22 on Friday. The firm's 50-day simple moving average is $7.73 and its 200 day simple moving average is $8.33. The firm has a market capitalization of $384.64 million, a PE ratio of -2.12 and a beta of 2.06. The company has a quick ratio of 9.06, a current ratio of 9.06 and a debt-to-equity ratio of 0.15. Kyverna Therapeutics has a 52 week low of $5.30 and a 52 week high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.05. On average, equities research analysts predict that Kyverna Therapeutics will post -2.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. WINTON GROUP Ltd acquired a new stake in Kyverna Therapeutics during the 2nd quarter worth about $155,000. IFP Advisors Inc purchased a new position in Kyverna Therapeutics during the second quarter valued at approximately $111,000. Spark Investment Management LLC acquired a new position in Kyverna Therapeutics in the 2nd quarter valued at approximately $224,000. Allianz Asset Management GmbH acquired a new position in Kyverna Therapeutics in the 2nd quarter valued at approximately $98,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Kyverna Therapeutics in the 2nd quarter worth approximately $404,000. 18.08% of the stock is owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases. The company is working to apply chimeric antigen receptor T-cell (CAR T) technology, traditionally used in certain blood cancers, to conditions in which the immune system attacks the body's own tissues.

Kyverna's lead investigational product, KYV-101, is an autologous, fully human CD19-directed CAR T-cell therapy designed to eliminate B cells that contribute to autoimmune disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.